Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee
Rona Therapeutics announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC),...
Others
Novo Nordisk CagriSema Pediatric Obesity Trial to Enroll 460 Children
Novo Nordisk (NYSE: NVO) is planning to test its experimental obesity drug CagriSema in overweight...
FDA Prasad Outlines New Vaccine Approval Process After Covid-19 Safety Analysis
Dr. Vinay Prasad, FDA’s chief medical and scientific officer, announced plans to overhaul the vaccine...
CSPC’s SYH2056 Wins NMPA Nod for Depression Trials as Fast‑Acting 5‑HT2A Agonist
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056, a selective 5‑HT2A receptor agonist, received...
Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline
Reprogenix Bioscience Inc. announced the completion of an oversubscribed RMB 500 million Series A+ financing round led...
NMPA Launches Pilot Program to Cut Review Time for Overseas‑Manufactured Drug Supplementary Applications
The National Medical Products Administration (NMPA) issued a formal notice today announcing a pilot program...
AnkeBio and PersonGen Ink Capital‑Increase Deal, Secure Exclusive Greater‑China Agency for PA3‑17 CAR‑T Therapy
Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today...
Mabwell Partners with Ping An Health to Launch Integrated Bone‑Health & Autoimmune Care Platform
Mabwell Bioscience (SHA: 688062) disclosed a strategic, deep‑level collaboration with Ping An Healthcare and Technology...
National Health Commission’s Negative Behavior List for Medical Staff Internet‑Based Health Science Popularization (Trial)
The National Health Commission (NHC) announced on 7 November 2025 a “Negative Behavior List for Medical Staff...
Sanofi’s Cablivi Wins China NMPA Approval – First Nanobody Drug for aTTP
Sanofi (NASDAQ: SNY) announced that its anti‑vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing...
Judge Rejects Pfizer’s Attempt to Block Novo Nordisk’s $10 bn Bid for Metsera
Delaware Court of Chancery Judge Morgan Zurn denied Pfizer’s (NYSE: PFE) request for a temporary...
Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds
Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first‑half 2025 financial results today,...
Shanghai Junshi Biosciences Secures First Canadian Approval for LOQTORZI (Toripalimab) in Nasopharyngeal Cancer
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced today that its programmed death‑1...
WuXi AppTec Sells WuXi Clinical and MedKey to Hillhouse for RMB 2.8 Billion
WuXi AppTec (Shanghai) Co., Ltd., a wholly‑owned subsidiary of Wuxi AppTec Co., Ltd. (SHA: 603259,...
Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC
Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted...
Prellis Biologics and Eli Lilly Announce AI‑Driven Antibody Discovery Collaboration
Prellis Biologics, Inc. and global biopharma leader Eli Lilly & Co. (NYSE: LLY) today announced...
GE Healthcare Eyes Sale of China Unit Amid Revenue Decline
GE Healthcare Technologies Inc. (NASDAQ: GEHC) is reportedly exploring the sale of a stake in...
China’s 11th National Drug VBP Draft Unveils Major Pricing & Competition Reforms
The second‑draft rules for China’s 11th round of national centralized drug procurement (VBP 11th) have...
Sanofi’s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP
The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi’s (NASDAQ: SNY) Wayrilz...
HitGen’s 2025 H1 Report Shows 16.58% Revenue Growth and 391% Profit Surge
China-based HitGen Inc. (SHA: 688222) on Aug 27, 2025 released its semi‑annual financial results for...